(A)

	Median (95%CI) OS (months)	1-year OS rate (%)	2-year OS rate (%)
Nivolumab	21 (17-25)	67.8	41.5
Pembrolizumab	20 (10-NA)	57.1	49.9

(B)

	Median (95%CI) PFS (months)	1-year PFS rate (%)	2-year PFS rate (%)
Nivolumab	7 (5-9)	32	25.4
Pembrolizumab	7 (2-12)	30.6	17

Figure S1. Kaplan–Meier curves of overall survival (**A**) and progression-free survival (**B**) according to the immune checkpoint inhibitors. Significant differences in OS and PFS were observed between Nivolumab and Pembrolizumab.